hepatitis

cancer target detection radiopharma radio

Biotech

Kezar drops solid tumor yet to prove its worth in phase 1 trial

Kezar Life Sciences is dropping its unpromising phase 1 solid tumor drug as the biotech goes all-in on its lead autoimmune hepatitis program.

James Waldron Aug 14, 2024 5:09am

stock market down crash fail shares

Durect fails alcohol-associated hepatitis trial, plans phase 3

Nov 8, 2023 7:57am